Quoin Pharmaceuticals, Ltd. - American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share (QNRX)
CUSIP: 74907L409
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share
- Shares outstanding
- 843,913
- Total 13F shares
- 1,491
- Share change
- -1,046
- Total reported value
- $10,716
- Price per share
- $7.09
- Number of holders
- 4
- Value change
- -$9,379
- Number of buys
- 1
- Number of sells
- 4
Quarterly Holders Quick Answers
What is CUSIP 74907L409?
CUSIP 74907L409 identifies QNRX - Quoin Pharmaceuticals, Ltd. - American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 74907L409:
Top shareholders of QNRX - Quoin Pharmaceuticals, Ltd. - American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
|
— |
5%
|
1,081,183
|
$7,049,313 | $0 | 31 Mar 2025 | |
| Denise P. Carter |
13D/G
|
Denise Carter |
4.9%
|
939,238
|
$244,202 | +$82,374 | 27 Jan 2025 | |
| Michael Myers |
13D/G
|
— |
4.9%
|
939,230
|
$244,200 | +$82,331 | 27 Jan 2025 | |
| Gordon Dunn |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
734,513
mixed-class rows
|
$67,985 | — | 23 Dec 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.15%
|
1,242
|
$11,448 | — | 30 Jun 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.08%
|
717
|
$6,618 | — | 30 Jun 2025 | |
| GAMMA Investing LLC |
13F
|
Company |
0.03%
|
240
|
$2,215 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.02%
|
206
|
$1,901 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
0.02%
|
130
|
$1,200 | — | 30 Jun 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
2
|
$18 | — | 30 Jun 2025 |
Institutional Holders of Quoin Pharmaceuticals, Ltd. - American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share (QNRX) as of Q3 2025
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.